Sanofi Reports Results of Zynquista (sotagliflozin) in P-III InSynchrony Program for Type2 Diabetes and Terminates Its Collaboration with Lexicon

Sanofi Reports Results of Zynquista (sotagliflozin) in P-III InSynchrony Program for Type2 Diabetes and Terminates Its Collaboration with Lexicon

Shots:

  • The three P-III studies (SOTA-MET, SOTA-CKD3, SOTA-CKD4) involves assessing of Zynquista vs PBO in patients with T2D. The first two studies resulted in meeting its 1EPs i.e, @26wks. reduction in HbA1c while SOTA-CKD4 did not demonstrate a reduction in HbA1c
  • Additionally, Sanofi to terminates its development and commercialization agreement with Lexicon for Zynquista in all ongoing global studies for T1D & T2D signed in Nov’2015 following the results of P-III InSynchrony program
  • Zynquista is an oral SGLT1 and SGLT2 inhibitor which are responsible for glucose absorption in GI tract & kidney respectively and has received approval as an adjunct to insulin therapy to improve glycemic control in patients with T1D Mellitus with BMI ≥ 27 kg/m2 in the EU

Click here to­ read full press release/ article | Ref: Sanofi | Image: Wsj